169 related articles for article (PubMed ID: 17109496)
1. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
Tonus C; Neupert G; Sellinger M
World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
3. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
4. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
5. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention.
Koss K; Maxton D; Jankowski JA
Colorectal Dis; 2008 Mar; 10(3):244-8. PubMed ID: 17784868
[TBL] [Abstract][Full Text] [Related]
6. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer.
Hardt PD; Mazurek S; Toepler M; Schlierbach P; Bretzel RG; Eigenbrodt E; Kloer HU
Br J Cancer; 2004 Aug; 91(5):980-4. PubMed ID: 15266315
[TBL] [Abstract][Full Text] [Related]
7. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA
J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277
[TBL] [Abstract][Full Text] [Related]
10. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
Tonus C; Sellinger M; Koss K; Neupert G
World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
[TBL] [Abstract][Full Text] [Related]
11. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
[TBL] [Abstract][Full Text] [Related]
12. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
[TBL] [Abstract][Full Text] [Related]
13. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
14. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
Li Y; Wang JJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
[TBL] [Abstract][Full Text] [Related]
16. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
[TBL] [Abstract][Full Text] [Related]
17. [Pilot study on M2-PK-- a new non-invasive parameter for early diagnosis of colorectal carcinoma].
Ivanova A; Iarŭmov N; Toshev S; Adzharov D; Krŭstev Z; Angelov K; Sokolov M; Gribnev P
Khirurgiia (Sofiia); 2007; (6):5-7. PubMed ID: 18622373
[TBL] [Abstract][Full Text] [Related]
18. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
[TBL] [Abstract][Full Text] [Related]
19. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
